These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 22294631)

  • 1. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
    Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.
    Beyer C; Zenzmaier C; Palumbo-Zerr K; Mancuso R; Distler A; Dees C; Zerr P; Huang J; Maier C; Pachowsky ML; Friebe A; Sandner P; Distler O; Schett G; Berger P; Distler JH
    Ann Rheum Dis; 2015 Jul; 74(7):1408-16. PubMed ID: 24567525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.
    Matei AE; Beyer C; Györfi AH; Soare A; Chen CW; Dees C; Bergmann C; Ramming A; Friebe A; Hofmann F; Distler O; Schett G; Distler JHW
    Ann Rheum Dis; 2018 Mar; 77(3):459. PubMed ID: 29311148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of pregnane X receptor inhibits experimental dermal fibrosis.
    Beyer C; Skapenko A; Distler A; Dees C; Reichert H; Munoz L; Leipe J; Schulze-Koops H; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2013 Apr; 72(4):621-5. PubMed ID: 23291432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
    Dees C; Beyer C; Distler A; Soare A; Zhang Y; Palumbo-Zerr K; Distler O; Schett G; Sandner P; Distler JH
    Ann Rheum Dis; 2015 Aug; 74(8):1621-5. PubMed ID: 25817717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis.
    Krönke G; Reich N; Scholtysek C; Akhmetshina A; Uderhardt S; Zerr P; Palumbo K; Lang V; Dees C; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Jun; 71(6):1081-7. PubMed ID: 22267335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart.
    Masuyama H; Tsuruda T; Sekita Y; Hatakeyama K; Imamura T; Kato J; Asada Y; Stasch JP; Kitamura K
    Hypertens Res; 2009 Jul; 32(7):597-603. PubMed ID: 19424280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
    Mittendorf J; Weigand S; Alonso-Alija C; Bischoff E; Feurer A; Gerisch M; Kern A; Knorr A; Lang D; Muenter K; Radtke M; Schirok H; Schlemmer KH; Stahl E; Straub A; Wunder F; Stasch JP
    ChemMedChem; 2009 May; 4(5):853-65. PubMed ID: 19263460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
    Stasch JP; Hobbs AJ
    Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
    Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
    Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.
    Stegemann A; Sindrilaru A; Eckes B; del Rey A; Heinick A; Schulte JS; Müller FU; Grando SA; Fiebich BL; Scharffetter-Kochanek K; Luger TA; Böhm M
    Arthritis Rheum; 2013 Mar; 65(3):792-804. PubMed ID: 23440693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.
    Stasch JP; Schlossmann J; Hocher B
    Curr Opin Pharmacol; 2015 Apr; 21():95-104. PubMed ID: 25645316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.